Trial Profile
Phase I study of pre-operative combination therapy with Mogamulizumab (anti-CCR4) and Nivolumab (anti-PD-1) against solid cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Mouth neoplasm; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics
- 05 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Jan 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2020.